Home Drug IndexClinical Monograph

Bimatoprost Eye Drops Uses, Side Effects, Dosage | DrugsAtlas

Authoritative Clinical Reference

PGF-2α analogues

DRUG NAME: Bimatoprost

Therapeutic Class:

Prostaglandin analogue

Subclass:

Antiglaucoma agent

Schedule (India):

Schedule H

Routes

Ophthalmic (topical)

Formulations Available in India

• Eye drops: 0.01% w/v (sterile ophthalmic solution, 3 mL bottle)
• Eye drops: 0.03% w/v (sterile ophthalmic solution, 3 mL bottle)
• Fixed-dose combinations with Timolol 0.5% available

ADULT INDICATIONS

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Open-Angle Glaucoma

Parameter	Details
Starting dose	1 drop of 0.03% solution in affected eye(s) once daily in the evening
Titration	Not required
Usual maintenance dose	1 drop once daily in the evening
Maximum dose	Once daily only — more frequent dosing paradoxically reduces efficacy
Clinical notes	Onset of action within 4 hours; peak IOP reduction at 8–12 hours; full therapeutic effect may take 2–4 weeks

2. Ocular Hypertension

Parameter	Details
Starting dose	1 drop of 0.03% solution in affected eye(s) once daily in the evening
Titration	Not required
Usual maintenance dose	1 drop once daily in the evening
Maximum dose	Once daily only
Clinical notes	Can be used as monotherapy or adjunctive therapy with beta-blockers or carbonic anhydrase inhibitors; if using multiple eye drops, maintain ≥5 minute interval between administrations

Secondary Indications – Adults Only (Off-label, if any)

Indication	Dose	Duration	Notes
Eyelash Hypotrichosis (OFF-LABEL, Specialist-only)	Apply thin layer of 0.03% solution to upper eyelid lash margin once daily at night using sterile applicator	12–16 weeks for visible effect	US FDA-approved for this indication; considered cosmetic in India; not standard ophthalmic use; results reverse upon discontinuation

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Glaucoma / Ocular Hypertension in Paediatric Patients

Age Group	Dosing	Notes
≥16 years	1 drop once daily in the evening (same as adult dose)	Safety profile similar to adults
3–15 years	1 drop once daily in the evening	OFF-LABEL — Limited paediatric data; use under specialist supervision only
<3 years	Not recommended	Insufficient safety data

Monitoring requirements:
• IOP measurement within 2 weeks of initiation
• Monitor for iris pigmentation changes at each visit
• Assess compliance and technique

Secondary Indications – Paediatric Doses (Off-label, if any)

• Not applicable — Cosmetic indications not appropriate for paediatric use

General Paediatric Statement

• Not recommended below age 3 years except under paediatric ophthalmologist supervision
• Limited long-term safety data in children
• Permanent iris pigmentation changes may occur

RENAL ADJUSTMENT

• No dose adjustment required
• Minimal systemic absorption from ophthalmic administration
• No specific studies in dialysis patients — use standard dosing

HEPATIC ADJUSTMENT

Severity	Recommendation
Mild impairment	No dose adjustment required
Moderate impairment	No dose adjustment required
Severe impairment	Use with caution; limited human data; minimal systemic exposure expected

CONTRAINDICATIONS

• Known hypersensitivity to bimatoprost, benzalkonium chloride, or any component of formulation
• Active intraocular inflammation (uveitis, iritis)
• Aphakia with torn posterior lens capsule
• Pseudophakia with torn posterior lens capsule or anterior chamber intraocular lens

CAUTIONS

• History of uveitis or iritis — may exacerbate inflammation
• Pre-existing macular oedema or risk factors for cystoid macular oedema (diabetic retinopathy, retinal vein occlusion, post-cataract surgery)
• History of herpetic keratitis — may reactivate
• Patients with mixed-colour irides — higher risk of permanent iris pigmentation
• Unilateral use — may cause noticeable asymmetry in iris colour, eyelash appearance, and periorbital skin
• Contact lens wearers — remove lenses before instillation; reinsert after 15 minutes
• Patients with corneal endothelial disease

PREGNANCY

Parameter	Recommendation
Safety category	Avoid unless essential — Prostaglandin analogues may have uterotonic effects
Preferred alternatives	Timolol eye drops (beta-blocker) — better safety profile in pregnancy
When used	Only if potential benefit justifies potential risk; specialist ophthalmology and obstetric input required
Monitoring	IOP control; routine fetal surveillance (no additional monitoring typically required due to minimal systemic absorption)

LACTATION

Parameter	Recommendation
Compatibility	Likely compatible — minimal systemic absorption expected
Preferred alternatives	Timolol eye drops if concerns persist
Expected drug levels in milk	Negligible (minimal systemic absorption from ophthalmic route)
Infant monitoring	Observe for feeding difficulties, unusual sedation, rash (unlikely)

ELDERLY

Parameter	Recommendation
Starting dose	Same as general adult dose (1 drop once daily in evening)
Titration	Not required
Special risks	Higher prevalence of ocular comorbidities (pseudophakia, macular disease); monitor for cystoid macular oedema
Monitoring	Regular IOP and macular assessment

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect	Recommendation
Other prostaglandin analogues (latanoprost, travoprost, tafluprost)	Concurrent use may paradoxically increase IOP	Avoid concomitant use of multiple prostaglandin analogues

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Recommendation
Topical NSAIDs (ketorolac, nepafenac)	May enhance ocular inflammatory response	Monitor for cystoid macular oedema, especially post-cataract surgery
Topical corticosteroids	May mask signs of ocular inflammation	Monitor IOP and inflammatory signs
Other antiglaucoma agents (timolol, brimonidine, dorzolamide)	Additive IOP-lowering effect (desirable)	Administer at least 5 minutes apart; commonly used together
Benzalkonium chloride-containing products	Cumulative ocular surface toxicity	Limit total exposure; consider preservative-free alternatives if using multiple drops

COMMON ADVERSE EFFECTS

• Conjunctival hyperaemia (most common, up to 45%)
• Eyelash changes (increased length, thickness, pigmentation, number)
• Ocular pruritus
• Eye dryness
• Burning or stinging sensation
• Foreign body sensation
• Periorbital skin darkening
• Eyelid erythema

SERIOUS ADVERSE EFFECTS

Adverse Effect	Clinical Action
Iris pigmentation (irreversible)	Counsel patient; more common in mixed-colour irides; may cause permanent heterochromia with unilateral use
Cystoid macular oedema	Discontinue; refer for retinal evaluation; more common in aphakic/pseudophakic patients
Uveitis/Iritis	Discontinue immediately; refer for specialist management
Herpetic keratitis reactivation	Discontinue; antiviral therapy
Periorbital fat atrophy (prostaglandin-associated periorbitopathy)	May cause enophthalmos, deepening of upper eyelid sulcus; consider switching to alternative class

MONITORING REQUIREMENTS

Timing	Parameters
Baseline	IOP measurement; iris colour documentation (photograph if possible); lens status; macular assessment in high-risk patients; history of uveitis/herpetic keratitis
After initiation (2–4 weeks)	IOP measurement; assess for hyperaemia, tolerance
Short-term (1–3 months)	IOP measurement monthly until stable; monitor iris and periocular changes
Long-term	IOP every 3–6 months; annual macular examination in high-risk patients (pseudophakia, diabetic retinopathy); document any iris colour changes

BRANDS AVAILABLE IN INDIA

Single-agent formulations:
• Lumigan (Allergan)
• Careprost (Sun Pharma)
• Bimat (Ajanta Pharma)
• Xovatra (Cipla)
• Bimato (Micro Labs)
• 3 Lat (Allergan — 0.01% formulation)

Fixed-dose combinations (Bimatoprost + Timolol 0.5%):
• Lumigan-T (Allergan)
• Bimat-T (Ajanta Pharma)
• Xovatra-T (Cipla)

PRICE RANGE (INR)

Formulation	Pack Size	Price Range
Bimatoprost 0.03% eye drops	3 mL	₹200–₹600
Bimatoprost 0.01% eye drops	3 mL	₹250–₹500
Bimatoprost + Timolol FDC	3 mL	₹300–₹700

• Not listed under NLEM
• Not under NPPA price control
• Significant price variation between branded and generic products

CLINICAL PEARLS

• Evening dosing is optimal — Prostaglandin analogues have greater IOP-lowering effect when administered in the evening
• Do not exceed once-daily dosing — More frequent instillation paradoxically reduces efficacy due to receptor downregulation
• Warn patients about permanent pigmentation — Iris darkening is irreversible; particularly important in unilateral use (may cause heterochromia)
• Consider 0.01% formulation — Similar efficacy with potentially fewer hyperaemia-related side effects
• Contact lens guidance — Remove lenses before instillation; wait 15 minutes before reinserting (benzalkonium chloride is absorbed by soft lenses)
• Prostaglandin-associated periorbitopathy (PAP) — Consider if patient develops deepening of upper lid sulcus, enophthalmos, or periorbital hollowing; may need to switch drug class
• Post-cataract surgery caution — Higher risk of cystoid macular oedema; monitor closely; may need to temporarily discontinue

VERSION

RxIndia v0.1 — 03 Feb 2026

REFERENCES

• CDSCO — Approved product labels
• Indian Pharmacopoeia / NFI 2016
• API Textbook of Medicine — Ophthalmology section
• AIIMS Ophthalmology Department protocols
• Harrison’s Principles of Internal Medicine, 21st edition
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th edition
• Peer-reviewed studies on prostaglandin analogues in glaucoma management

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...